Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/ITGB1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ITGB1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ITGB1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/ITGB1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ITGB1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ITGB1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ITGB1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ITGB1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ITGB1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ITGB1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0010769110 | Skin | SCCIS | regulation of cell morphogenesis involved in differentiation | 13/919 | 96/18723 | 8.15e-04 | 1.10e-02 | 13 |
GO:004484315 | Skin | SCCIS | cell cycle G1/S phase transition | 24/919 | 241/18723 | 8.16e-04 | 1.10e-02 | 24 |
GO:0032956112 | Skin | SCCIS | regulation of actin cytoskeleton organization | 32/919 | 358/18723 | 8.18e-04 | 1.10e-02 | 32 |
GO:000170413 | Skin | SCCIS | formation of primary germ layer | 15/919 | 121/18723 | 8.61e-04 | 1.14e-02 | 15 |
GO:000008215 | Skin | SCCIS | G1/S transition of mitotic cell cycle | 22/919 | 214/18723 | 8.70e-04 | 1.14e-02 | 22 |
GO:005165619 | Skin | SCCIS | establishment of organelle localization | 34/919 | 390/18723 | 8.85e-04 | 1.15e-02 | 34 |
GO:00987421 | Skin | SCCIS | cell-cell adhesion via plasma-membrane adhesion molecules | 26/919 | 273/18723 | 9.83e-04 | 1.23e-02 | 26 |
GO:001059415 | Skin | SCCIS | regulation of endothelial cell migration | 23/919 | 232/18723 | 1.10e-03 | 1.34e-02 | 23 |
GO:00550941 | Skin | SCCIS | response to lipoprotein particle | 7/919 | 34/18723 | 1.13e-03 | 1.36e-02 | 7 |
GO:1904375110 | Skin | SCCIS | regulation of protein localization to cell periphery | 15/919 | 125/18723 | 1.21e-03 | 1.42e-02 | 15 |
GO:0001701110 | Skin | SCCIS | in utero embryonic development | 32/919 | 367/18723 | 1.23e-03 | 1.45e-02 | 32 |
GO:1902903112 | Skin | SCCIS | regulation of supramolecular fiber organization | 33/919 | 383/18723 | 1.27e-03 | 1.49e-02 | 33 |
GO:001072111 | Skin | SCCIS | negative regulation of cell development | 19/919 | 180/18723 | 1.40e-03 | 1.59e-02 | 19 |
GO:20002732 | Skin | SCCIS | positive regulation of signaling receptor activity | 8/919 | 45/18723 | 1.40e-03 | 1.59e-02 | 8 |
GO:00714023 | Skin | SCCIS | cellular response to lipoprotein particle stimulus | 7/919 | 36/18723 | 1.61e-03 | 1.79e-02 | 7 |
GO:003009813 | Skin | SCCIS | lymphocyte differentiation | 32/919 | 374/18723 | 1.67e-03 | 1.84e-02 | 32 |
GO:001081213 | Skin | SCCIS | negative regulation of cell-substrate adhesion | 10/919 | 68/18723 | 1.69e-03 | 1.85e-02 | 10 |
GO:00329632 | Skin | SCCIS | collagen metabolic process | 13/919 | 104/18723 | 1.72e-03 | 1.87e-02 | 13 |
GO:1903076111 | Skin | SCCIS | regulation of protein localization to plasma membrane | 13/919 | 104/18723 | 1.72e-03 | 1.87e-02 | 13 |
GO:006024916 | Skin | SCCIS | anatomical structure homeostasis | 28/919 | 314/18723 | 1.74e-03 | 1.88e-02 | 28 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ITGB1 | SNV | Missense_Mutation | | c.2050N>G | p.Gln684Glu | p.Q684E | P05556 | protein_coding | tolerated(0.27) | benign(0.006) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ITGB1 | SNV | Missense_Mutation | | c.445A>C | p.Met149Leu | p.M149L | P05556 | protein_coding | deleterious(0.03) | benign(0.398) | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD |
ITGB1 | SNV | Missense_Mutation | | c.826T>C | p.Phe276Leu | p.F276L | P05556 | protein_coding | tolerated(0.09) | probably_damaging(0.998) | TCGA-BH-A1F6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ITGB1 | SNV | Missense_Mutation | rs758287253 | c.1474N>T | p.Asn492Tyr | p.N492Y | P05556 | protein_coding | deleterious(0) | possibly_damaging(0.494) | TCGA-E2-A14S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
ITGB1 | insertion | Nonsense_Mutation | novel | c.1500_1501insCAGCTCTAATCCTCATAACAGTCCTGTGCCTAGAA | p.Glu501GlnfsTer3 | p.E501Qfs*3 | P05556 | protein_coding | | | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ITGB1 | insertion | Nonsense_Mutation | novel | c.560_561insCTCTAGATGACCTTCTTTGATTTTAGAGGCCTCTTAGTGG | p.Val188SerfsTer3 | p.V188Sfs*3 | P05556 | protein_coding | | | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ITGB1 | SNV | Missense_Mutation | novel | c.1982N>A | p.Cys661Tyr | p.C661Y | P05556 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
ITGB1 | SNV | Missense_Mutation | | c.337N>G | p.Gln113Glu | p.Q113E | P05556 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ITGB1 | SNV | Missense_Mutation | novel | c.1480G>C | p.Gly494Arg | p.G494R | P05556 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-MA-AA3Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ITGB1 | SNV | Missense_Mutation | novel | c.2216N>C | p.Gly739Ala | p.G739A | P05556 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | FIRATEGRAST | FIRATEGRAST | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | 131I-radretumab | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL2109621 | ABITUZUMAB | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | antagonist | CHEMBL2108061 | VOLOCIXIMAB | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | JSM 6427 | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | 385612210 | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | inhibitor | CHEMBL1201607 | NATALIZUMAB | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | F200 | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | R1295 | | |
3688 | ITGB1 | DRUGGABLE GENOME, KINASE, CELL SURFACE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE | | GLPG0187 | GLPG-0187 | |